Castle Biosciences (CSTL) Common Equity (2018 - 2026)

Castle Biosciences has disclosed Common Equity across 9 years of filings, most recently posting $461.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $461.4 million, up 4.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $461.4 million (up 4.79% YoY), and the FY2025 annual result was $470.9 million, up 3.3% from the prior year.
• Common Equity came in at $461.4 million for Q1 2026 at Castle Biosciences, down from $470.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $470.9 million in Q4 2025 to a low of $378.8 million in Q2 2023.
• The 5-year median for Common Equity is $421.7 million (2022), against an average of $422.9 million.
• Across the five-year window, Common Equity retreated 10.17% in 2023 and climbed 16.5% in 2024, its largest moves.
• Castle Biosciences' Common Equity stood at $399.2 million in 2022, then slipped by 1.97% to $391.3 million in 2023, then climbed by 16.5% to $455.8 million in 2024, then advanced by 3.3% to $470.9 million in 2025, then slipped by 2.01% to $461.4 million in 2026.
• The last three Common Equity figures came in at $461.4 million (Q1 2026), $470.9 million (Q4 2025), and $467.0 million (Q3 2025), per Business Quant data.